Otonomy Otividex Fails in Phase 3 Ménière's Trial

[wizman]

Good luck to this company for the other trials.
Otonomy is one of the few to take risks for research for chronic tinnitus.

 

[Reinier]

I am somewhat surprised that nobody feels this is in particular bad news for people that suffer from Ménière's disease.
Perhaps somebody commented on that and I missed it .

 

[attheedgeofscience]

I see yet another thread on TinnitusTalk has once again spun off in all possible directions leaving a cloud of vitriol and misinformation behind. A sight to see. As always...

 

[Kratos]

I hope so, but it doesn't explain why some of those with a loss and corrected with a hearing aid don't see any change in tinnitus, or when the audiotory nerve is cut - sometimes it fixes it sometimes it doesn't, there are so many unanswered questions we cannot assume it will work. That's why it's important other avenues for fixing tinnitus are addressed and supported.

Neither hearing aids nor cutting the auditory nerve restores the normal input.

 

[vermillion]

I see yet another thread on TinnitusTalk has once again spun off in all possible directions leaving a cloud of vitriol and misinformation behind. A sight to see. As always...

The side effects of freedom of speech.

 

[jeff W]

I am somewhat surprised that nobody feels this is in particular bad news for people that suffer from Ménière's disease.
Perhaps somebody commented on that and I missed it .

I am in contact with a large community of md sufferers who follow the research of their disease closely, believe me, they were not expecting anything special. This was a steroid trial, not some hi-tech cell treatment. There is the standard of peer review and there is the standard of the market (in terms of application value), the observable reality is that otonomy meets neither. The risks they took were with other people's money. As I have said before, Auris and Otonomy may be useful to us, only in that they are lessons for the other ear corps of how not to proceed. They were only giving themselves an award a few months back for being great, now they won't even communicate with shareholders.

 

[Flamingo1]

As I have stated this again and again, once they stop testing this on mice and instead test it on any animal that more closely resembles a human. Only at that point will we see some good progress in drug testing.

I beg to differ. Mice are important (and can't sue when experiments go wrong!)
https://www.genome.gov/10001345/importance-of-mouse-genome/

 

[Paulmanlike]

I am in contact with a large community of md sufferers who follow the research of their disease closely, believe me, they were not expecting anything special. This was a steroid trial, not some hi-tech cell treatment. There is the standard of peer review and there is the standard of the market (in terms of application value), the observable reality is that otonomy meets neither. The risks they took were with other people's money. As I have said before, Auris and Otonomy may be useful to us, only in that they are lessons for the other ear corps of how not to proceed. They were only giving themselves an award a few months back for being great, now they won't even communicate with shareholders.

View attachment 13640

Yes but remember they are piggy backing of Auris AM-101 to watch it flop first (hopefully not) before they will proceed with OTO-311. I hope regardless of the results of AM-101 and the recent failed OTIVIDEX is not enough reason to delay/abort OTO-311 - this is the drug most of us are all rooting for.

I don't know if anybody mentioned either that there is another MD drug being tested in phase 3 and I can't remember the name or company of it - but it might be worth mentioning for any MD sufferers here to root for that now that this one has failed.

 

[vermillion]

OTO-311 - this is the drug most of us are all rooting for.

Isn't that only for acute phase tinnitus?
Btw I found it pretty sad that Otividex failed. A possible success could give relief to MD patients and it would mean one step forward in understanding the inner ear.

 

[Paulmanlike]

Isn't that only for acute phase tinnitus?
Btw I found it pretty sad that Otividex failed. A possible success could give relief to MD patients and it would mean one step forward in understanding the inner ear.

We don't know if it's intended only for acute or for both yet (we are waiting for the Q&A with TT and Otonomy) but I would expect it to be only for acute given the link to Rnid above. That's not to say it won't be tested for chronic sufferers though. But I wouldn't expect them to move forward with phase 2 if AM-101 shows another failed attempt at proving efficacy with results expected in January I think. (Because of the similar MOA)